97th DOG Annual Meeting 1999



T. Schlote, M. Derse, B. Wannke, H.-J. Thiel, B. Jean

Diode laser cyclophotocoagulation (DLCPC) is a new cyclodestructive procedure for the treatment of refractory, advanced glaucoma. Information about the effectivity of this procedure is still lacking. First results of a prospective study are presented.

Methods: Fifty-four eyes of 54 patients with advanced, refractory glaucoma were consecutively treated with DLCPC. The patients were followed for one year after first treatment. Successful treatment was defined as 1. a decrease of IOP to 5-21 mmHg in eyes with a visual acuity of 1/50 or more; 2. a decrease of IOP < 30mmHg in eyes with a visual acuity of less than 1/50 (including blind eyes) or relief of pain.

Results: A follow-up of one year was achieved in 51 of 54 eyes. Forteen eyes had inflammatory glaucoma, 9 open angle glaucoma, 9 neovascular glaucoma, 8 traumatic glaucoma, and 11 other types of glaucoma. Before DLCPC, 31 eyes had been treated with other surgical procedures for glaucoma, and 31 eyes had other surgical procedures (pseudophakia n=15, aphakia n=13). DLCPC was successful in 37 eyes (72,5%). Twenty-eight eyes (55 %) required one or more repeat treatments. Within the follow-up, another surgical procedure was performed in 7 eyes (13,7%) to control IOP. No serious side effects occured.

Conclusions: This study suggests that DLCPC is an effective, safe method in the treatment of advanced glaucoma. In comparison to cyclocryocoagulation, DLCPC is associated with fewer side effects.

University Eye Clinic, Department of Experimental Ophthalmic Surgery, Tuebingen